US Pharma MarketingDiamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout addiction diabetes Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout BeOne wins FDA approval in lymphoma race Diamantas takes the reins, Regenxbio stakes claim in…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Biotech’s cell therapy boom keeps expanding beyond cancer: CREATE Medicines just raised $122 million to advance its in vivo CAR-T for autoimmune disease into the clinic.
Meanwhile, the Trump administration is searching for a new FDA commissioner, setting up a politically fraught fight over the agency’s future direction.
Source: STAT News Pharma